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Lifestyle, mainly dietary, interventions are first-line treatment for women with polycystic
ovary syndrome (PCOS), but the optimal diet remains undefined. We combined a hyper-
androgenized PCOS mouse model with a systematic macronutrient approach, to elucidate the
impact of dietary macronutrients on the development of PCOS. We identify that an optimum
dietary macronutrient balance of a low protein, medium carbohydrate and fat diet can
ameliorate key PCOS reproductive traits. However, PCOS mice display a hindered ability for
their metabolic system to respond to diet variations, and varying macronutrient balance did
not have a beneficial effect on the development of metabolic PCOS traits. We reveal that
PCOS traits in a hyperandrogenic PCOS mouse model are ameliorated selectively by diet,
with reproductive traits displaying greater sensitivity than metabolic traits to dietary mac-
ronutrient balance. Hence, providing evidence to support the development of evidence-based
dietary interventions as a promising strategy for the treatment of PCOS, especially repro-
ductive traits.
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Polycystic ovary syndrome (PCOS) is the most commonendocrine disorder estimated to affect 8–13% of women ofreproductive age worldwide1–3. PCOS is a heterogeneous
disorder encompassing reproductive, metabolic and endocrine
abnormalities, including hyperandrogenism, ovulatory dis-
turbance, reduced fertility and a higher incidence of obesity,
insulin resistance, hepatic steatosis, and dyslipidemia, which
heighten the risk of type 2 diabetes and cardiovascular disease1,4.
The prevalence of weight excess in PCOS is in the range of
30–75%5,6, and obesity worsens symptoms of PCOS7–9, while
weight loss improves its features5. The 2018 international
evidence-based guideline for the assessment and management of
PCOS recommends that lifestyle intervention, including diet,
exercise and behavioral strategies, should be implemented to all
women with PCOS10. However, the optimal dietary composition
to be incorporated into a lifestyle management plan aimed at
improving the clinical features of PCOS remains unknown.
There is a paucity of well-controlled studies on dietary impacts
on PCOS and further research is needed5,8. Studies within the
limited literature available suggest that in women with PCOS,
high fat diets aggravate obesity and PCOS traits7. Studies of the
effects of low11 and high protein11–13, and low14,15 and high
carbohydrate12 are also reported. Low carbohydrate diets are
reported to exert greater reductions in insulin resistance and total
cholesterol than standard diets8, with an additional 1–5% sig-
nificantly greater weight loss14. While a modified hypocaloric diet
with a high-protein, low glycaemic load results in significantly
increased insulin sensitivity16, these studies also demonstrate that
overall weight loss has a beneficial effect on PCOS features
regardless of dietary composition. Indeed, a critical review of the
literature identified that improvements in many key features of
PCOS occur with a modest weight loss of 5–15%17. A recent
systematic review assessing dietary effects on PCOS outcomes
identified that the body of evidence was not sufficient to draw
reliable conclusions about the optimal dietary composition for
lifestyle management in PCOS8.
Current guidelines recommend a 5–10% weight loss over
6 months in overweight women with PCOS as it improves clinical
outcomes10. Nevertheless, energy-restricted dietary interventions
have notoriously low long-term compliance. Moreover, weight
management is difficult, with attrition a common problem, which
appears to be even worse in PCOS patients, with a Cochrane
review reporting attrition rates in lifestyle intervention studies of
up to 46% in women with PCOS18. Furthermore, weight man-
agement interventions may be less effective in women with PCOS
than in women without PCOS, based on the observation that
longitudinal weight gain is greater in women with PCOS19.
Despite their reported higher motivation to follow healthy weight
management practices than women without PCOS, women with
PCOS are still heavier20. This indicated change in response to diet
may be explained by factors driving PCOS, such as hyperan-
drogenism and insulin resistance, which can alter energy home-
ostasis, appetite and/or metabolism, but this remains unclear.
Before an optimum dietary composition for the management
of PCOS can be identified, the knowledge gap on the impact of
macronutrient balance on PCOS features must be addressed.
Rigorous and systematic research is needed to provide a basis for
the development of testable nutritional strategies to be translated
into human clinical studies21. However, human diet studies are
commonly constrained by poor compliance beyond short-term
trials; hence it is difficult to draw firm conclusions on optimum
diets for sustained benefits. In contrast to human studies, iden-
tifying the principles of optimal macronutrient composition is
more tractable in a rigorously controlled environment setting,
such as in animal models. Carefully designed experiments using
animal models that display characteristics of the human
condition of PCOS with high fidelity are valuable tools as they
afford insights into fundamental biological mechanisms impact-
ing on the development of PCOS. To date, systematic experi-
mental studies to elucidate the optimum diet for amelioration of
PCOS traits have not been reported.
Previously, we combined the mouse as a mammalian model
and the Geometric Framework (GF), a powerful nutritional
approach, to analyze the individual and interactive effects of
protein, carbohydrate and fat on reproductive and metabolic
function22,23. We revealed that reproductive function and cardi-
ometabolic health are strongly impacted by the macronutrient
balance of the diet23,24, therefore we hypothesized that dietary
macronutrient balance will have a significant impact on the
development of PCOS features. In this study, we combined a
PCOS mouse model25,26 with the GF to evaluate the effect of
dietary macronutrients (protein, carbohydrate and fat) on traits
of PCOS. Our findings reveal that the development of PCOS traits
is influenced by dietary macronutrient balance. We show that the
reproductive PCOS feature of ovulatory dysfunction can be res-
cued by an optimized dietary composition. Hyperandrogenic
PCOS mice exhibit a limited ability for their metabolic system to
respond to variations in diet, and alterations in dietary macro-
nutrient balance have a minimal beneficial effect on ameliorating
metabolic PCOS traits.
Results
DHT treatment validation and response surface interpretation.
We evaluated the effects of dietary macronutrient balance on the
development of reproductive and metabolic features of PCOS in
PCOS and control female mice with dihydrotestosterone (DHT)-
induced experimental PCOS. DHT treatment was validated by
liquid chromatography-tandem mass spectrometry (LC-MS/MS),
with PCOS mice (1.34 ± 0.17 ng/ml) exhibiting a significant
increase in circulating DHT levels compared to control females
(0.27 ± 0.04 ng/ml, P < 0.001). Serum testosterone levels were also
assessed and in agreement with our previous studies25,26, levels
were observed to be comparable between control (0.07 ± 0.01 ng/
ml) and PCOS (0.05 ± 0.02 ng/ml) females. Using the GF nutri-
tional modeling method, cohorts of control and DHT-induced
PCOS mice were each confined to one of ten diets that varied
systematically in protein (P), carbohydrate (C), and fat (F) con-
tent, which allowed us to plot a landscape profile of different
PCOS phenotypes onto macronutrient intakes (Supplementary
Fig. 1 and Supplementary Table 1).
Response surfaces to diet for the various features of PCOS
assessed are presented in three graphs of 2D nutrient spaces, with
each cut through the median of the third nutrient axis (value
provided in parenthesis below the x-axis label). The 2D slices
visualize the impact of all three macronutrient dimensions
(protein, P; carbohydrate, C; fat, F represented on the x and y
axis) on the outcomes being assessed. The outcome (e.g., corpora
lutea number, Fig. 1e) is represented on the colored surface as a
contour, with the number on the surface being the outcome value.
To determine differences in the presence of PCOS-like traits in
response to diet, 3D GAM response surfaces are provided
showing the difference in response between control and PCOS
mice to macronutrients. All surfaces are interpreted statistically
using general additive statistical models (GAMs)23,24 or mixture
models (Sheffe’s polynomials) and results are provided in
Supplementary Tables 2 and 3. GAMs are a form of multiple
regression, which allow for the quantification of non-linear effects
of multi-dimensional predictors (e.g., dietary intake of P, C, and
F) on response variables (e.g., metabolic/reproductive parameters)
using non-parametric smoothing functions (here thin-plate and
cubic-regression splines).
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Selective macronutrient intakes rescue ovulatory dysfunction.
Irregular menstrual cycles and ovulatory dysfunction are key
diagnostic features of PCOS10. In this study, irrespective of diet
and consistent with our previous studies25,26, PCOS mice
exhibited a significant disturbance of ovulatory function with a
decrease in corpora lutea (CL) number (0.5 ± 0.2) compared to
control mice (4.5 ± 0.6) (P < 0.001, Fig. 1a–c). However, CL were
present within the ovaries of a subset (8/35) of PCOS mice
(Fig. 1d). We used response surfaces to detail the effects of all
three macronutrients on CL response. All control mice ovulated
and displayed maximal CL numbers on dietary intakes of <20 kJ/
day C and 10–25 kJ/day F, shown by the area circled in red (CxF
P= 0.033; Fig. 1g and Supplementary Table 2). The majority








































































0 5 10 15 20 25 0 10 20 30 40 50 60
Protein eaten (kJ/day)
(Fat: 13)





0 10 20 30 40 50 60
Carbohydrate eaten (kJ/day)
(Protein: 8)
0 10 20 30 40 50 60
Carbohydrate eaten (kJ/day)
(Protein: 8)
0 10 20 30 40 50 60
Carbohydrate eaten (kJ/day)
(Protein: 8)
0 10 20 30 40 50 60
Carbohydrate eaten (kJ/day)
(Protein: 8)

































































































































































PCOS corpora lutea number: Influence of macronutrient intake
f g
i j
k Control PCOS Response difference between groups































0 1 2 3 4 5 6 7 8 9 10 11 12
Days




















C = 20 kJ/day





500 µm 500 µm 500 µm
Control PCOS PCOSb c d C: 20–30 kJ/day
F: 15–25 kJ/day
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19003-5 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5262 | https://doi.org/10.1038/s41467-020-19003-5 | www.nature.com/naturecommunications 3
demonstrated by the lack of CL in their ovaries (Fig. 1c) and by
the dark blue areas on the response surfaces (Fig. 1h–j). However,
the response surface identified that CL were observed in PCOS
mice that ingested a tightly defined combination of 20–30 kJ/day
C and 15–25 kJ/day F, at a median of 8 kJ/day P, highlighted by
the area circled in red (Fig. 1j). Response surfaces demonstrated
that the combination of C and F intakes was the main driver of
ovulation in control and PCOS mice (shown by red/yellow hot-
spots in Fig. 1g, j, Supplementary Table 2). Therefore, we sub-
tracted C-F response surfaces derived from control mice (Fig. 1k)
from those generated from PCOS animals (Fig. 1l) in order to
identify how control and PCOS mice differed in their response to
diet (Fig. 1m). The ovulatory response to diet in control and
PCOS mice was comparable when they ingested >20 kJ/day C and
>25 kJ/day F (shown by non-significant gray area Fig. 1m). In
contrast on intakes of <20 kJ/day C and <25 kJ/day F, control and
PCOS mice had significantly different responses to diet (shown
by pink-purple area Fig. 1m). These findings demonstrate that
control mice are able to maintain ovulations on a wide range of
dietary intakes, while PCOS mice are only able to ovulate under a
narrower nutritional niche. In agreement with our previous
studies25,26, circulating FSH and LH levels were not altered
between control and PCOS mice (Supplementary Fig. 2a and 3a)
and both groups displayed similar responses to diet (Supple-
mentary Fig. 2b-j and 3b-j). However, diet-induced restoration in
ovulatory function in PCOS females was confirmed by examining
estrous cycle patterns in control and PCOS mice (Fig. 1n-r and
Supplementary Fig. 4). A proportion of PCOS mice cycled (15/
94), demonstrated by the finding that some PCOS mice were
observed to spend time at all stages of the estrous cycle (Fig. 1n).
While the majority of PCOS mice were acyclic, corresponding
with the macronutrient balance able to restore ovulatory function
in PCOS mice, a subset of PCOS mice within the intake ranges of
20–30 kJ/day C and 15–25 kJ/day F displayed completed estrous
cycles (Fig. 1q and Supplementary Fig. 4g).
PCOS caused weight increase regardless of dietary intake.
Women with PCOS exhibit a higher rate of weight gain and a
higher prevalence of obesity compared to women without
PCOS19,27. Regardless of dietary intervention, PCOS mice dis-
played a significant increase in body weight (23.5 ± 0.3 g) com-
pared to control mice (21.7 ± 0.2 g) (P < 0.001, Fig. 2a), which is
in agreement with previous studies using our hyperandrogenized
PCOS mouse model25,26. The increased weight gain in PCOS
females was reflected by an increase in body fat content (P <
0.001) and also lean mass (P < 0.001) (Fig. 2b–e). Parametrial,
retroperitoneal, mesenteric and brown fat depot weights were all
significantly increased in PCOS mice compared to control mice
(P < 0.05, Fig. 2c). Response surfaces show that all three macro-
nutrients influenced weight gain and that there is a similar color
shift from blue to red along the P, C, and F axis in both control
and PCOS mice (Fig. 2f–k, Supplementary Table 2). These data
imply that in both groups body weight follows the same pattern of
response to macronutrient intake, with body weight increasing as
caloric intake of P, C, and F increased (Fig. 2f–k). However,
PCOS mice were observed to gain substantially more weight at
lower caloric intakes than control mice. This is exemplified in
PCOS mice on lower intakes for each macronutrient, as they were
found to be significantly heavier than control mice with the same
P, C, or F intakes (Fig. 2l–n). Moreover, analysis of changes in
response to diet for body weight between control and PCOS mice
confirmed that PCOS mice were more sensitive to macronutrient
intake, with PCOS mice gaining significantly more weight com-
pared to control mice at low C and low F intakes of <25 kJ/day
each (P < 0.05, Fig. 2q).
To identify reasons for this observed selective increase in body
weight in PCOS mice, we assessed total food and energy intake
against dietary composition. Food and energy (food intake ×
energy (kJ) per gram P, C, and F in diet) intakes were plotted as
response surfaces onto diet composition axis and interpreted
statistically using mixture models (Scheffe’s polynomials)
(Fig. 3a–d, Supplementary Table 3). Both control and PCOS
mice exhibited the same eating patterns with food and energy
intake decreasing as protein content increased as expected,
evidenced by the red to blue color shift along the P axis
(Fig. 3a–d); ruling out increased food and energy intake as a
potential cause for PCOS mice exhibiting an increase in weight
gain. Instead, it implies a difference in post-ingestive responses to
diet intake. In an additional dietary choice study, PCOS mice
displayed no significant difference in their preference for P, C, or
F compared to control mice (Fig. 3e). Furthermore, metabolic
cage analysis of the control and PCOS mice, 1 week prior to the
dietary choice study, consuming a standard chow diet revealed
there was no significant difference between the two groups for
day and night food intake, indirect calorimetry measurements of
energy expenditure, body weight corrected energy expenditure,
oxygen consumption (vO2), carbon dioxide expulsion (vCO2),
respiratory exchange ratio (RER), and night locomotor activity
(Table 1). Although PCOS mice exhibited lower day locomotor
activity, this difference was relatively small and unlikely to be
sufficient to fully explain the increase in body weight in PCOS
mice. Hence, these data imply that although PCOS mice exhibited
the same eating pattern, caloric intake, and activity as control
mice, the underlying androgen excess driven pathogenesis of
PCOS caused the PCOS mice to gain significantly more weight at
intakes of <25 kJ/day C and <25 kJ/day F (Fig. 2q). However,
Fig. 1 An optimal dietary macronutrient balance rescues ovulatory dysfunction in a PCOS mouse model. a Number of corpora lutea (CL) in control and
PCOS mice, showing that regardless of diet PCOS mice exhibit fewer CL (P < 0.001). Significance determined by Mann–Whitney test, asterisk (*) indicates
P-value <0.05. b–d Representative histological control (b) and PCOS (c) ovarian cross-sections, showing presence of CL in ovaries from PCOS mice with a
macronutrient intake of C 20–30 kJ/day and F 15-25 kJ/day (d). White stars, corpora lutea. Magnification ×4, scale bar 500 µm. e–j 3D GAM response
surfaces showing the relationship between macronutrient intake (kJ/day) and number of CL in control (e–g) and PCOS ovaries (h–j) showing restoration of
ovulations in PCOS mice on a macronutrient intake of C 20–30 kJ/day and F 15–25 kJ/day (j). Red areas indicate the greatest value, which then decreases to
the lowest value as the color shifts to blue. Regions with highest CL number for control (g) and PCOS (j) mice are encircled in red. k–m 3D GAM response
surfaces showing the impact of main drivers (carbohydrate and fat) on CL numbers in control mice (k), PCOS mice (l) and the response difference (m),
demonstrating a comparable ovulatory response between control and PCOS above a C intake of >20 kJ/day and F > 25 kJ/day. a, e–m n= 36 control and 35
PCOS mice. n % of time spent at each stage of the estrous cycle for control and PCOS mice, showing that a subset of PCOS mice did cycle through all
estrous cycle stages. Significance determined by Mann–Whitney test, asterisk (*) indicates P-value <0.05, all P < 0.001. o–q Representative graphs of
estrous-cycle patterns, showing restoration of cyclicity in a PCOS mouse with a dietary intake of 20 kJ/day C and 21 kJ/day F (q). r Response difference
between control and PCOS mice for number of estrous cycles completed, demonstrating comparable estrous cycle response between control and PCOS
mice at similar intakes that restore ovulatory response. n, r n= 93 control and 94 PCOS mice. a, n Data presented as violin plots, doted lines indicate the
median and dashed lines the 25 and 75% percentiles.
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when C and F intakes were more than 25 kJ/day, body weight,
although still greater in PCOS mice, was influenced similarly by
macronutrient intake in PCOS and control mice (Fig. 2q).
Diet variations do not impact PCOS traits in adipose tissue.
When data across all diets was combined, hyperandrogenism
induced a significant increase in adipocyte area within PCOS
parametrial fat pads compared to control mice (1729 ± 54.3 µm2
vs. 1573 ± 50.6 µm2) (P= 0.04, Fig. 4a, b). This finding is in
agreement with previous mouse PCOS studies26,28. Analysis of
changes in response to diet for adipocyte size, revealed the same
pattern as changes in response to diet for body weight between
control and PCOS mice. PCOS mice were more sensitive to low
macronutrient intakes, but otherwise both groups displayed
comparable patterns of response to macronutrient intake
(Fig. 4c). Adiponectin is an adipokine that is reduced in serum of
PCOS patients29–31 and PCOS animal models26,30. In this study,
adiponectin levels were significantly decreased in PCOS females
compared to control females (11221 ± 453.8 ng/ml vs. 16806 ±
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758.7 ng/ml) (P < 0.001, Fig. 4d). In response to diet, adiponectin
levels most strongly increased with increasing C intake in control
mice (P= 0.002), however P intake also exerted an influence over
adiponectin levels (P= 0.032, Fig. 4e, g, Supplementary Table 2).
In contrast, in PCOS mice macronutrient intake had no sig-
nificant influence on adiponectin levels, shown by the monotone
blue response surfaces across all diets (Fig. 4h–j). Hence, revealing
that diet was not able to modify the androgen excess-driven
aberrant adipocyte function in PCOS mice. This difference in
response is clearly visualized after the subtraction of C–F
response surfaces of control (Fig. 4k) and PCOS mice (Fig. 4l),
where the majority of control and PCOS mice exhibit a sig-
nificantly different response to macronutrient intake for serum
adiponectin levels (shown by purple in Fig. 4m).
Cholesterol in PCOS mice is minimally impacted by diet.
Regardless of dietary intervention, there was a trend for
PCOS mice to exhibit an increase in serum cholesterol levels
(61.5 ± 2.7 mg/dL) compared to controls (53.1 ± 2.2 mg/dL, P=
0.06; Fig. 5a). Response surfaces revealed that control mice were
readily able to regulate serum cholesterol levels on a wide range of
macronutrient intakes, as control mice displayed consistent, low
levels of circulating cholesterol, as shown by the overall hue of
blue (Fig. 5b–d). In contrast, serum cholesterol levels in PCOS
mice was highly affected by F intake, with increasing F con-
sumption leading to increased serum cholesterol levels, as seen by
the change of color from blue to red along the F axis (P < 0.001,
Fig. 5f–g, Supplementary Table 2). The subtraction of serum
cholesterol C–F response surfaces of control mice (Fig. 5h) and
PCOS mice (Fig. 5i) showed largely a significant difference in
response (Fig. 5j) to diet between the two groups. This finding
revealed that overall macronutrient intake minimally influenced
cholesterol levels in control mice, and implies that the underlying
androgen excess driven pathogenesis of PCOS caused the PCOS
mice to have a reduced ability to regulate their cholesterol levels
in response to changes in macronutrient intake. Irrespective of
Fig. 2 PCOS mice gain excess weight regardless of macronutrient balance. a Body weight; regardless of diet PCOS mice exhibit increased body weight
(P < 0.001). b Body fat (g), calculated by dual-energy x-ray absorptiometry (DEXA), showing that PCOS mice display a significant increase in body fat (P=
0.0005). c Fat depot weights showing a significant increase in adiposity in PCOS mice (P < 0.05). d Lean body mass (g) calculated by DEXA, showing that
PCOS mice exhibit a significant increase in lean body mass (P < 0.001). a–d Significance determined by Mann–Whitney test, asterisk (*) indicates P-value
<0.05. e Representative DEXA images of a control and PCOS mouse, showing development of increased adiposity in PCOS mouse. f–k 3D GAM response
surfaces showing the relationship between macronutrient intake (kJ/day) and body weight in control (f–h) and PCOS (i–k) mice. Red areas indicate the
greatest value, which decreases to the lowest value as the color shifts to blue. Response surfaces show that dietary macronutrient intake influenced
body weight similarly in control and PCOS mice, as color shifts from blue to red along the P, C, and F axis. Direct comparison of control and PCOS mice on
<10 kJ/day P (l), n= 56 control and 62 PCOS mice, <20 kJ/day C (m), n= 74 control and 68 PCOS mice and <20 kJ/day F intakes (n), n= 76 control and
70 PCOS mice, demonstrate that PCOS mice are significantly heavier than control mice on similar P, C, and F intakes (P < 0.001). o–q 3D GAM response
surfaces showing the effects of C and F intakes on body weight in control mice (o), PCOS mice (p) and the response difference (q), revealing PCOS mice
exhibited a significantly different (higher) body weight compared to control mice at C and F intake <25 kJ/day. Above a C and F intake of 25 kJ/day, PCOS
mice exhibit a comparable body weight response to macronutrient intake as controls. a–d, f–k, o–q, n= 93 control and 94 PCOS mice. a–d, l–n Data
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Fig. 3 PCOS and control mice exhibit similar eating habits and dietary preference. Response surfaces showing food intake of control (a) and PCOS
(b) mice and energy intake of control (c) and PCOS (d) mice across 10 different diets varying in protein (P), carbohydrate (C), and fat (F) content,
demonstrating that PCOS mice exhibit the same eating pattern as control mice, as dietary protein increases, food and energy intake decreases. Red areas
indicate the greatest value for each response, which then decreases to the lowest value as the color shifts to blue. a–d n= 93 control and 94 PCOS mice.
eMacronutrient intake (kJ/day) of control and PCOS mice when given a choice between 3 diets (high P (60%), high C (75%), and high F (75%)), showing
no significant difference in macronutrient preference between control and PCOS mice. e n= 17 control and 16 PCOS mice. e Data presented as violin plots,
doted lines indicate the median and dashed lines the 25 and 75% percentiles.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19003-5
6 NATURE COMMUNICATIONS |         (2020) 11:5262 | https://doi.org/10.1038/s41467-020-19003-5 | www.nature.com/naturecommunications
diet and consistent with our previous study26 PCOS mice did not
display a significant increase in serum triglyceride levels (Sup-
plementary Fig. 5a). Triglycerides levels in control and PCOS
mice were driven by P intake (P < 0.05, Supplementary Fig. 5b-d),
and P and C intakes (P < 0.05, Supplementary Fig. 5e-g),
respectively, but overall levels were within a similar range for both
groups (40–65 mg/dL). In line with this, analysis of changes in
response to diet between control and PCOS mice showed overall
comparable responses to diet between both treatment groups
(Supplementary Fig. 5j).
Fasting glucose in PCOS mice is minimally affected by diet.
Women with PCOS often display elevated fasting glucose levels
due to insulin resistance32. Irrespective of dietary intervention,
fasting glucose levels were significantly elevated in PCOS mice
compared to control mice (9.2 ± 0.2 mmol/L vs. 8.8 ± 0.2 mmol/L,
P < 0.05; Fig. 6a), consistent with previous findings in our
hyperandrogenized PCOS mouse model26. Response surfaces
indicated that control mice exhibited superior stability over
fasting glucose levels on different macronutrient intakes, with the
majority of mice exhibiting glucose levels of ~8.5 mmol/L,
observed in green-yellow (Fig. 6b–d). In contrast, PCOS mice
displayed impaired control over fasting glucose levels with the
majority exhibiting levels of 9.5 mmol/L or above across varying
macronutrient intakes (Fig. 6e–g). Specifically, PCOS mice were
influenced most by P and F intake, with increased P leading to the
highest levels of fasting glucose in this group (Fig. 6e–f, Supple-
mentary Table 2). Subtraction of C–F response surfaces of control
(Fig. 6h) and PCOS mice (Fig. 6i), showed that the majority of
PCOS mice on F intakes >12 kJ/day were unable to regulate
serum fasting glucose to comparable levels observed in control
mice (Fig. 6j). This result revealed that overall variations in
macronutrient intake had a limited influence on fasting glucose
levels in control mice; however, the presence of androgen excess-
driven PCOS pathology significantly reduced the capability of
PCOS mice to modulate glucose levels in response to diet. GTT
response was also assessed and irrespective of diet and consistent
with our previous studies25,26, PCOS mice did not display an
altered GTT response to control mice (Supplementary Fig. 6a),
with both groups displaying similar GTT AUC across the
majority of dietary intakes (Supplementary Fig. 6b–g). Corre-
spondingly, analysis of changes in response to diet between
control and PCOS mice identified no difference in response to
diet between both groups for GTT response (Supplementary
Fig. 6h–j).
Discussion
Nutritional manipulations are one of the most widely-applicable
and practical interventions shown to impact health in a wide
range of mammals33. Hence, defining the optimal, balanced
macronutrient dietary treatment for PCOS is of great practical
interest, as dietary interventions would be an extremely appealing
therapeutic approach to clinically manage PCOS pathology.
However, this is challenging to achieve in humans due to the
logistical challenges of diet design and compliance over prolonged
periods required for sustained weight loss.
In this study, we utilized a PCOS mouse model that replicates
numerous reproductive and metabolic features of human PCOS to
gain insight into the basic principles on the individual and inter-
active effects of protein, carbohydrate and fat on the development
of PCOS features. By combining an experimental PCOS mouse
model with the GF nutritional modeling approach, we provide
evidence that macronutrient balance is an important factor in the
development of PCOS traits. Our data show that the PCOS traits of
acyclicity and anovulation can be rescued by a specific dietary
macronutrient balance, supporting the use of dietary manipulation
as a potential viable strategy to be used to assist in restoration of
ovulatory dysfunction in women with PCOS. In agreement with
previous studies25,26,34, ovulatory function is aberrant in the
hyperandrogenic mouse model of PCOS as corpora lutea popula-
tions are diminished. However, ovulatory function was restored in
PCOS females on a tightly defined intake range of protein, car-
bohydrate and fat, indicated by the presence of corpora lutea in
their ovaries (8/35), which conclusively confirms the occurrence of
recent ovulations. This restoration in ovulatory function in PCOS
females was confirmed by the presence of complete estrous cycles
in PCOS mice (15/94) on the same dietary macronutrient balance
able to restore ovulation.
This finding reinforces clinical evidence supporting the use of
lifestyle interventions in the treatment of dysfunctional menstrual
Table 1 Metabolic state does not differ between control and PCOS mice.
Control PCOS Significance
Day
Food intake (g) 0.56 ± 0.06 0.49 ± 0.06 Ns
Locomotor activity (beam breaks) 14180 ± 662.8 12291 ± 552.9 0.037
Energy expenditure (kcal/12 h) 50.6 ± 2.6 51.5 ± 3.3 Ns
Energy expenditure (kcal/12 h/kg) 2144 ± 107.5 2019 ± 98.23 Ns
VO2 (ml/12 h/kg) 7448 ± 371.4 6988 ± 338.8 Ns
VCO2 (ml/12 h/kg) 5764 ± 301.9 5521 ± 275.3 Ns
RER (VCO2/VO2) 0.77 ± 0.01 0.79 ± 0.01 Ns
Control PCOS Significance
Night
Food intake (g) 2.26 ± 0.13 2.38 ± 0.13 Ns
Locomotor activity (beam breaks) 45748 ± 1660 46087 ± 2219 Ns
Energy expenditure (kcal/12 h) 70.3 ± 3.3 75.6 ± 3.2 Ns
Energy expenditure (kcal/12 h/kg) 2960 ± 139.70 2957 ± 99.69 Ns
VO2 (ml/12 h/kg) 10071 ± 469.7 10045 ± 348 Ns
VCO2 (ml/12 h/kg) 8723 ± 435.1 8763 ± 267.3 Ns
RER (VCO2/VO2) 0.85 ± 0.01 0.87 ± 0.01 Ns
Measurements of indirect calorimetry by metabolic cages of control and PCOS mice on a standard chow diet, showing food intake (g), locomotor activity (beam breaks), energy expenditure (kcal/12 h),
body weight corrected energy expenditure (kcal/12 h/kg), oxygen (O2) consumption (VO2), carbon dioxide (CO2) produced (VCO2), and respiratory exchange ratio (RER) do not differ between control
and PCOS mice. Data are the mean ± SEM; n= 17 control and 16 PCOS mice.
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cycling and ovulation for infertile women with PCOS. In a pre-
vious study comparing the use of medical treatment (clomiphene
citrate, metformin) vs. lifestyle modification (reduction in energy
intake and an increase in physical activity) in patients with PCOS,
it was observed that lifestyle modification effectively improved
rates of menstrual cycles and clinical pregnancies to levels com-
parable with those reported in the clomiphene citrate and met-
formin treated women35. Furthermore, in another study using a
structured exercise training and hypocaloric dietary intervention
alone or together with clomiphene citrate in overweight women
with PCOS, the lifestyle intervention alone significantly improved
the metabolic and endocrine profile, and ovulation rate when in
combination with clomiphene citrate36. However, these studies
do not take into account macronutrient balance and at present
there is a paucity of high quality literature in this area, hindering
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into human clinical studies. The results of this study demonstrate
that macronutrient balance does impact the development of
reproductive PCOS traits and that an optimal dietary macro-
nutrient balance of low protein and medium carbohydrate and
fat dietary consumption can rescue ovulatory dysfunction
observed in a PCOS mouse model. These findings provide sup-
port for the future development of an evidence-based nutritional
strategy for the treatment of PCOS reproductive traits. Notably,
the dietary macronutrient ratio identified (14% P, 47% C, and
39% F) falls within the ranges of a traditional Mediterranean diet,
which has been associated with numerous health benefits such
as improvement of lipid profile, protection against oxidative
stress37,38, decreased adiposity39 and decreased risk of type-2
diabetes40. A recent study has reported that women with PCOS
with a high adherence to a Mediterranean diet presented with
lower testosterone and HOMA-IR levels41. Thus, further studies
defining if this beneficial effect on PCOS traits is attributed to the
macronutrient balance alone or the food choices associated with a
Mediterranean diet are warranted.
Obesity is common in women with PCOS5,6 and obesity itself
worsens symptoms of PCOS7–9. Consistent with this, research
using animal models has identified that hyperandrogenism leads to
increased body weight in PCOS animal models42 and high fat and
western-style diets exaggerate androgen excess-induced metabolic
features of PCOS43–45. Findings from this study have revealed that
while protein, carbohydrate and fat intake are all key drivers of
weight gain in both control and PCOS mice, PCOS mice displayed
an increased sensitivity in response to diet compared to controls, as
PCOS females gained more weight at lower macronutrient intakes
than control mice. Congruent with our research findings, in a
comprehensive review on the effect of different dietary composi-
tions on outcomes in women with PCOS, only subtle differences
were found between diets8,46. It was concluded that from the
current information available, the best approach for a clinical
benefit in overweight women with PCOS was a diet aimed at
reducing body weight, regardless of dietary composition8. How-
ever, it was also noted that limited evidence is currently available
and further research is required from high quality long-term RCTs
assessing a range of dietary compositions8.
Women with PCOS have been described as having significantly
poorer dietary habits characterized by a greater consumption of
high glycaemic index foods47,48 and a decreased basal metabolic
rate49. A significantly higher intake of energy from carbohydrates
and a corresponding higher respiratory exchange ratio has also
been reported in women with PCOS50. On the other hand, other
studies have reported that women with and without PCOS dis-
play similar dietary habits and energy intake from protein, car-
bohydrate and fat consumption51,52. In fact in one study
comparing women with and without a self-reported PCOS
diagnosis, while women with PCOS reported a higher energy
intake, there was no difference in protein, carbohydrate or fat
percent energy intake and actually better dietary intake in terms
of diet quality, micronutrient, saturated fat and glycaemic index
intake53. In our study we observed the same pattern for energy
intake and no significant difference in macronutrient preference
between control and PCOS mice. Moreover, evaluation of
metabolic state in control and PCOS mice, using metabolic cages,
revealed that overall metabolic measurements, including energy
expenditure and RER, did not differ significantly between groups.
This finding is congruent with the reported observation that
women with PCOS do not have a different resting metabolic rate
to women without PCOS50. Hence, taken together these findings
infer that hyperandrogenism does not drive notable changes in
eating habits, dietary preference or sedentary activity, but rather
that hyperandrogenism decreases the capacity of the metabolic
system to cope with poorer diets.
Adiponectin, a protein hormone secreted by adipocytes, has
been reported to be reduced in women with PCOS31,54,55, and
insufficient levels linked with the development of insulin resis-
tance in murine models of obesity56. Overexpression of adipo-
nectin in an androgen excess-induced mouse model of PCOS was
discovered to maintain healthy metabolic parameters of PCOS,
while in contrast a loss of adiponectin caused DHT-induced
PCOS mice to become even more insulin resistant than their
control DHT-exposed littermates28. Furthermore, exogenous
administration of adiponectin rescues reproductive and metabolic
PCOS-like traits in two different rodent models of PCOS30,57. In
this study, PCOS females exhibited an increase in adipocyte size
compared to controls, with altered function evident by a sig-
nificant decrease in serum adiponectin levels. These data are in
agreement with our and other animal models of PCOS26,28,57 and
previous clinical reports stating that women with PCOS tend to
have low levels of adiponectin compared to women without
PCOS31,54,55. Moreover, the current data demonstrate that
alterations in dietary macronutrient balance were unable to
beneficially influence adiponectin levels in PCOS mice. It has
been reported that women with PCOS exposed to either a
hypocaloric diet with a standard macronutrient balance or a
hypocaloric diet with a low carbohydrate and high protein bal-
ance both displayed an increase in adiponectin levels. The authors
concluded the increase in adiponectin was most likely due to
weight loss rather than the alteration in macronutrient balance16.
Our findings agree with this as we show that different macro-
nutrient ratios were not able to significantly change adiponectin
levels, indicating that diet is not a key influence on the man-
agement of adiponectin levels in a PCOS population. Instead, we
propose that hyperandrogenism is at the root of adipose tissue
dysfunction, which is supported by the finding that normal serum
adiponectin levels are maintained by a global loss of androgen
receptor function in a hyperandrogenized PCOS mouse model26.
Fig. 4 Macronutrient balance does not modulate adipocyte hypertrophy or elevated adiponectin levels in a PCOS mouse model. a Histological sections
of representative parametrial fat pads from a control and PCOS mouse, showing development of adipocyte hypertrophy only in PCOS mice. Magnification
×40, scale bar 50 µm. b Adipocyte area, showing that regardless of diet PCOS mice exhibit adipocyte hypertrophy (P= 0.04). Significance determined by
two-tailed Student’s t test, asterisk (*) indicates P-value <0.05. c Response difference between control and PCOS mice for adipocyte area, showing that
adipocyte size in PCOS mice was significantly increased at low carbohydrate and fat intakes. b–c n= 35 control and 38 PCOS mice. d Serum levels of
adiponectin, showing that irrespective of diet PCOS mice exhibit lower serum adiponectin levels (P < 0.001). Significance determined by two-tailed
Student’s t test, asterisk (*) indicates P-value <0.05. e–j 3D GAM response surfaces displaying the relationship between macronutrient intake (kJ/day) and
serum adiponectin levels in control (e–g) and PCOS mice (h–j), showing a global decrease of adiponectin in PCOS mice irrespective of macronutrient
intakes. Red areas indicate the greatest value for each response, which then decreases to the lowest value as the color shifts to blue. k–m Response
surfaces showing the effects of C and F intakes on adiponectin levels in control mice (k), PCOS mice (l), and the response difference (m), demonstrating
that overall adiponectin levels are significantly different between control and PCOS mice, consequently serum adiponectin levels in PCOS mice are heavily
influenced by the PCOS pathophysiology and not diet. d–m n= 78 control and 87 PCOS mice. b, d Data presented as violin plots, doted lines indicate the
median and dashed lines the 25 and 75% percentiles.
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Dyslipidemia, a risk factor for cardiovascular disease, is pre-
valent in women with PCOS58. A meta-analysis showed that in an
age-matched population of women with and without PCOS,
women with PCOS displayed higher levels of LDL-cholesterol
and non HDL-cholesterol, and that even when matched for BMI,
women with PCOS still exhibited higher LDL-cholesterol levels
than controls59. Lifestyle modification improves the lipid profile
in PCOS women35 and improvements of cholesterol levels are
observed under hypocaloric conditions regardless of diet
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Fig. 5 Increased cholesterol level in PCOS mice is driven by PCOS pathophysiology and cannot be modulated via diet. a Serum cholesterol levels,
showing that regardless of diet androgen excess leads to a non-significant increase in serum cholesterol levels (P= 0.06). Significance determined by
Mann–Whitney test. Data presented as violin plots, doted lines indicate the median and dashed lines the 25 and 75% percentiles. b–g 3D GAM Response
surfaces displaying the relationship between macronutrient intake (kJ/day) and serum cholesterol levels in control (b–d) and PCOS mice (e–g), showing
that macronutrient intake had no influence on cholesterol levels in control mice, while F intake was the main driver for increased serum cholesterol levels in
PCOS mice (f, g). Red areas indicate the greatest value for each response, which then decreases to the lowest value as the color shifts to blue. h–j 3D GAM
response surfaces showing the effects of C and F intakes on serum cholesterol levels in control mice (h), PCOS mice (i) and response difference (j),
showing that overall cholesterol levels in PCOS mice are significantly different to control mice due to the underlying pathophysiology of PCOS. However,
serum cholesterol levels in PCOS females reached comparable levels to control when F intake was reduced to <20 kJ/day. a–j n= 91 control and 89
PCOS mice.
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of either a therapeutic lifestyle changes diet or a pulse-based diet
in women with PCOS, those on the pulse diet had a greater
decrease in cardio-metabolic risk factors such as LDL-cholesterol
and insulin response to OGTT60. As previously reported25,26, our
PCOS mouse model mimics PCOS associated dyslipidemia, with
an increase in serum cholesterol levels. In this study, control mice
were readily able to regulate their serum cholesterol levels over a
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Fig. 6 Increased fasting glucose levels in PCOS overall cannot be ameliorated by dietary interventions. a Fasting glucose levels, showing a significant
increase in basal glucose levels in PCOS mice compared to control mice (P= 0.04). Significance determined by Mann–Whitney test, asterisk (*) indicates
P-value <0.05. Data presented as violin plots, doted lines indicate the median and dashed lines the 25 and 75% percentiles. b–g 3D GAM response
surfaces displaying the relationship between macronutrient intake (kJ/day) and glucose levels in control (b–d) and PCOS mice (e–g). Red areas indicate
the greatest value for each response, which then decreases to the lowest value as the color shifts to blue. Control mice exhibited a decrease in fasting
glucose with increasing fat intake while PCOS mice display overall increased levels of fasting glucose. h–j Response surfaces showing the effects of C and F
intakes on fasting glucose levels in control mice (h), PCOS mice (i) and response difference (j), demonstrating that fasting glucose levels in PCOS mice
are comparable to control mice when fat intake was reduced to <12 kJ/day. On the other hand, fasting glucose is not able to be modulated by diet when
PCOS mice ingested F in the range of 12–32 kJ/day, indicating that PCOS pathology hinders serum fasting glucose levels in PCOS mice with higher
F intakes. a–j n= 93 control and 94 PCOS mice.
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displayed an impaired ability to regulate their cholesterol levels in
response to changes in macronutrient intake, and serum choles-
terol levels was highly affected by fat intake, with increasing fat
consumption leading to increased serum cholesterol levels.
Therefore, we propose that the hyperandrogenic PCOS environ-
ment is the key cause of dyslipidemia in PCOS females. This
notion is supported by other animal studies where a global and
neuron-specific loss of androgen receptor signaling prevented
androgen excess-induced dyslipidemia26. In terms of macro-
nutrients, decreasing dietary fat intake led to a decrease in serum
cholesterol levels in PCOS females. This is in agreement with
previous studies, where exposing PCOS mice to a high fat diet
exacerbated the metabolic phenotype of PCOS44.
The pattern of PCOS females being unable to regulate adipo-
nectin and cholesterol across various diets, also extended to their
inability to regulate serum glucose levels. In our study, as per our
previous publications26,34, impaired glucose homeostasis was
observed in PCOS females. This finding is consistent with studies
in humans where women with PCOS have increased levels of
steady state plasma glucose and fasting glucose compared to non-
PCOS women32. A lifestyle intervention combining exercise and a
hypocaloric diet in women with PCOS reduced fasting insulin
levels and HOMA-IR, but not fasting glucose levels36. In this
study, fasting glucose levels were significantly elevated in PCOS
mice compared to control mice, and overall glucose levels were
unable to be restored to control levels by the wide range of dietary
modifications. Control mice exhibited superior stability over
fasting glucose levels on a wide range of macronutrient intakes,
while PCOS mice displayed brittle control over fasting glucose
levels. This finding implies that, as was the case with adiponectin
and cholesterol regulation, the presence of androgen excess dri-
ven PCOS pathology significantly reduced the capability of PCOS
mice to modulate glucose levels in response to varying diets.
The identification of an optimal dietary intervention for PCOS
is of high importance as it would provide a widely feasible and
cost-effective nutritional strategy for women worldwide suffering
from PCOS. By combining the multidimensional nutritional GF
with a PCOS mouse model, we have shed light on the impact of
all three macronutrients, protein, carbohydrate and fat, on the
development of different PCOS features. We reveal that ovulatory
dysfunction and acyclicity can be rescued in our PCOS mouse
model through the use of an optimal dietary intervention, indi-
cating that dietary macronutrient composition should be con-
sidered when planning an optimal diet to assist in the
management of PCOS-induced infertility. The finding that PCOS
mice gained more weight at lower macronutrient intakes than
control mice, supports implementation of the current clinical
recommendations of weight loss and exercise for all women with
PCOS. Hyperandrogenic PCOS mice also displayed a decreased
capacity for their metabolic system to respond to variations in
diet, and changes in macronutrient balance had a minimal ben-
eficial effect on ameliorating metabolic dysfunction observed in
PCOS mice. These findings support the notion that the under-
lying pathophysiology of PCOS has a predominant influence on
the development of PCOS traits. Overall, we provide insight into
the principles of macronutrient balance on PCOS traits, and
strong evidence to support a place for the use of dietary inter-
ventions in the management of PCOS, in particular future
development of evidence-based nutritional strategies for the
treatment of PCOS reproductive traits.
Methods
Mice and diets. C57Bl/6J female mice were housed in groups of 2 or 3 mice per
cage (4–5 cages per diet) and maintained under standard housing conditions (ad
libitum access to food and water in a temperature-controlled and humidity-con-
trolled, 12-h light/dark environment) at the ANZAC Research Institute.
Specifically, room temperature set point is 22+/− 1 °C and room humidity is
between 60 and 70%. At 7 weeks of age, control and DHT-induced PCOS mice
were switched from standard chow diet and provided ad libitum access to one of 10
experimental diets varying in protein, carbohydrate, and fat content (Specialty
Feeds). The selection of macronutrient content used in the experimental diets was
chosen, based on our previous publications23,24, for optimal power in fitting
response surface models used for statistical analysis (Supplementary Fig. 1 and
Supplementary Table 1). Ten control mice/diet were provided ad libitum access to
diets 1, 2, 4–10. 10 PCOS mice/diet were provided ad libitum access to diets 1, 2,
4–9, and 11 mice for diet 10. Diet 3 was discontinued after 6 control and 6 PCOS
mice experienced a weight loss of ≥20% or failed to thrive. Hence, data from diet 3
is from 3 control and 3 PCOS mice that completed the 10 weeks of experimental
diet exposure. Body weight was measured weekly for 10 weeks. For accurate food
intake measurements and hence energy intake quantification, a custom-made, two-
chamber Perspex insert was placed in each cage to ensure all food spillage could be
collected and accounted for. Measurement of the amount of food consumed was
performed once a week for 10 weeks and corrected for food spillage. Prior to
collection estrous cycles and body composition were assessed. 10 weeks post-diet,
187 female mice were anesthetized using a 1:1 ratio of ketamine and xylazine,
euthanized and blood and various tissues were collected and analyzed. All mouse
experiments complied with all relevant ethical standards regarding animal research.
All experiments were approved by the Sydney Local Health District Animal
Welfare Committee within National Health and Medical Research Council
guidelines for animal experimentation.
Generation of PCOS mouse model. PCOS was induced by peripubertal andro-
genization25. In short, 3-week-old C57Bl/6J female mice were implanted sub-
cutaneously with a 1-cm SILASTIC brand implant (id, 1.47 mm; od, 1.95 mm, Dow
Corning Corp, catalog no. 508–006) containing ~10 mg DHT or an empty pellet as
a control. Silastic implants are made in-house and provide steady-state DHT
release for at least 6 months61. At the time of animal collection all implants were
removed and checked to ensure they still had DHT powder in them (which they
did) and had not ruptured or leaked.
Ovary preparation and morphological analysis. Ovaries were dissected, weighed,
fixed in 4% (weight/vol) paraformaldehyde overnight at 4 °C, and stored in 70%
(vol/vol) ethanol before histological processing and analysis. Ovaries were pro-
cessed through graded alcohols and embedded in glycol methacrylate resin
(Technovit 7100; Heraeus Kulzer). 36 control and 35 PCOS ovaries (minimum 3
ovaries per treatment/diet) were assessed. Embedded ovaries were sectioned at 20
μm, stained with periodic acid-Schiff and counterstained with haematoxylin. For
corpora lutea quantification, whole-section scans of every third section were taken
under a light microscope using the DP70 Olympus camera.
Assessment of estrous cycle. Estrous-cycle stage was analyzed using vaginal
epithelial cell smears taken daily for 11 consecutive days. Smears were collected
using 15 μL of 0.9% sterile saline and transferred to glass slides to air dry. Dry
smears were stained with 0.5% toluidine blue before examination under a light
microscope. Estrous-cycle stage was determined based on the presence or absence
of leukocytes, cornified epithelial cells, and nucleated epithelial cells. Proestrus was
characterized by the presence of mainly nucleated and some cornified epithelial
cells; at the estrous stage, mostly cornified epithelial cells were present; at metestrus,
both cornified epithelial cells and leukocytes were present; and at diestrus, pri-
marily leukocytes were present.
DHT and testosterone levels. Serum DHT and testosterone levels (extracts of
100 μl of mouse serum) were assessed by liquid chromatography-tandem mass
spectrometry (LC-MS/MS)62. The limits of quantitation (defined as the lowest level
that can be detected with a CV of <20%) were 0.05 ng/ml for DHT and 0.01 ng/ml
for testosterone.
LH and FSH levels. Blood was collected from females by cardiac exsanguination
under ketamine/xylazine anesthesia, and collected serum was stored at −20 °C.
Mice were collected at the diestrus stage for cycling mice and pseudo-diestrus for
acyclic PCOS mice. FSH and LH levels in 10 µl of sera diluted in 15 µl serum
dilution buffer (1 in 2.5 dilution) was measured using EMD Millipore’s MILLI-
PLEX®MAP 96-well Mouse Pituitary Magnetic Bead custom Kit (Cat# MPTMAG-
49K) according to manufacturer’s instructions (EMD Millipore, Billerica, MA,
USA). Luminex MAGPIX instrument (Luminex Corporation, Northbrook, IL,
USA) calibrated with MAGPIX Calibration and Performance Verification Kits
(Millipore) with xPONENT software (Luminex) was used to acquire data. Saved
data was then analyzed as the Median Fluorescent Intensity (MFI) using spline
curve-fitting for calculating analyte concentrations in samples with Multiplex
Analyst software Version 5.1 (Luminex).
Body composition. Body composition was assessed in all mice by dual-energy X-
ray absorptiometry (DEXA) using the GE PIXImus2 Series Densitometer (GE
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Medical Systems Ultrasound and BMD) under isoflurane inhalation anesthetic on
week 10 of the diet.
Adipose tissue analysis. Parametrial fat pads were weighed, fixed in 4% paraf-
ormaldehyde, embedded in paraffin, sectioned at 8 μm and stained with haema-
toxylin and eosin. To assess adipocyte cell size, five different pictures were taken
from each of three sections of the fat pad, with a minimum of 200 μm separating
these sections. Images were taken at ×40 magnification under the Olympus BX60
light microscope for histomorphometric analysis. Adipocyte area was quantified
using ImageJ version 1.51 software (NIH). All parametrial fat pads were analyzed
without knowledge of treatment group.
Adiponectin assay. Total full-length mouse adiponectin were measured in serum
using a Quantikine ELISA Kit from R&D Systems (MRP300) according to man-
ufacturer’s instructions. The mean minimum detectable dose of mouse adiponectin
was 0.003 ng/ml.
Cholesterol and triglyceride levels. Serum total cholesterol and triglyceride levels
were assayed enzymatically with kits obtained from Wako (Cholesterol E Kit, 439-
17501; Triglyceride Kit, 432-40201).
Fasting glucose levels and glucose tolerance test. Fasting glucose levels and
intraperitoneal glucose tolerance test (ipGTT) were measured on week 10 of the
diet. Mice were fasted for 6 h before a baseline blood glucose reading, followed by
an i.p. injection of glucose at 2 g/kg BW. Blood glucose was then measured at 15,
30, 60, and 90 min. Blood was obtained from a tail vein puncture, and blood
glucose was measured using glucose strips on an Accu-Chek glucometer (Roche).
Metabolic cage and diet preference study. Four month old C57Bl/6J female
mice (17 control and 16 DHT-induced PCOS) were housed individually in
metabolic chambers (Mouse Promethion caging system, Sable SystemsTM, Las
Vegas, USA) and maintained under standard housing conditions (ad libitum access
to chow food and water in a temperature-controlled and humidity-controlled, 12-h
light/dark environment) at the ANZAC Research Institute. 72 h (3 dark and 3 light
cycles) of measurements were included for analysis and were taken after mice were
acclimatized for 2 days. Each cage had flow‐through respirometer to monitor
metabolic rates, and sensor technology to monitor food, water uptake and body
mass. Movement was also detected using infrared beam breaks in axis X, Y, and Z.
Mice were then housed in standard cages and maintained under standard housing
conditions for 1 week. Subsequently, these same mice were provided with ad
libitum access to three different diets with either high protein (60% P, 20% C, 20%
F), high carbohydrate (75% C, 5% P, 20% F) or high fat (75% F, 5% P, 20% C)
content (Specialty Feeds) for 7 days (2 days acclimatization, 5 days of measure-
ment). Food intake was measured daily for 4 days and body weight recorded at the
start and end of exposure to the experimental diet. To account for food waste, a
custom designed 2-chambre Perspex insert was installed beneath the food hopper
of each cage which also allowed for the 3 diet separation within the cage for
accurate measurement.
Statistical modeling and analysis. Macronutrient and food intake were analyzed
based on average intake per mouse per cage per day. All other outcomes are
modeled for individual animals. Data that were not normally distributed were log
transformed before analysis or handled using appropriate link-functions. Non-
detectable DHT steroid samples were treated as the value set for the limit of
detection corrected with a data substitution method to minimize left censoring bias
in serum steroid measurements63. Nondetectable LH and FSH samples were
treated as the lowest value detected. Data are presented using the Geometric
Framework approach, visualized through response surfaces and analyzed using
generalized additive modeling (GAM) using the mgcv package in R v3.5.1., and
through mixture-models using the mixexp package64,65. All surfaces are color
coded across both control and PCOS groups, with red the highest elevation and
blue the lowest in the pooled data from both surfaces. For data using counts, GAMs
were fitted with the negative binomial distribution (log-link). In all cases, surfaces
are presented on the raw scale to aid in interpretation (i.e., back transformed after
model fitting). Comparisons between control and PCOS treatment groups were
performed using Prism 8 software (GraphPad Software, Inc). Data that was nor-
mally distributed was analyzed using a Student’s t-test, while a non-parametric
Mann–Whitney test was used for data that was not normally distributed. Pro-
portions were analyzed by Fisher’s exact test. P values <0.05 were considered
statistically significant. Comparisons are presented as violin plots with median and
quartile values indicated by dotted lines and a bar graph for proportional data. Data
values in the result section are presented as mean ± SEM.
Surface subtraction. For each overlapping point on the two predicted surfaces we
estimated the difference (d) as:
d ¼ y1  y2; ð1Þ
where y1 is the estimate on the first surface and y2 is the estimate on the second. To
estimate the significance of each point of difference we calculate a confidence limit
(CFL) around the difference and, where that CFL excluded zero we inferred a
significant difference. CFLs were calculated via Eqs. (2) and (3):






where q is a constant specifying the width of the CFL (1.96, 2.58, and 3.29, for 95,
99, and 99.9%, respectively) and SE1 and SE2 are the predicted standard errors for
the points on the two surface66,67. In cases where outcomes were transformed, or
modeled using a link function, CFLs were constricted on the latent scale, before
overall surfaces were back transformed for interpretation.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The raw data that supports the findings in this study has been deposited in a publicly
accessible database [https://github.com/AlistairMcNairSenior/GFN_PCOS]. Source data
are provided with this paper.
Code availability
Custom codes have been deposited in a publicly accessible database [https://github.com/
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